Craig Masse

Role: Ajax Therapeutics
Location: Cambridge, MA, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

Experience

Ajax Therapeutics
Present

Skills

Drug Design
Virtual Screening
Chemistry
Drug Discovery
Organic Synthesis
Patent Applications
Technology Transfer
Lifesciences
Life Sciences
Medicinal Chemistry
Biochemistry
Clinical Development
Pharmaceutical Industry
Drug Metabolism
Biotechnology
Infectious Diseases
Drug Repositioning
Drug Development
Organic Chemistry
Lead Optimization

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@ajaxtherapeutics.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Ajax Therapeutics

Biotechnology Research · 12 employees

Ajax is pursuing uniquely selective approaches to develop novel next generation therapies for hematologic cancers, including myeloproliferative neoplasms (MPNs). By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms, we aim to discover and develop more precisely designed therapies to address the significant unmet needs for patients with MPNs, including myelofibrosis, which are driven by aberrant JAK/STAT signaling due to mutations in JAK2, MPL and CALR genes. Our focus is developing next-generation JAK2 inhibitors that address the significant unmet needs of patients with myelofibrosis (MF) including the treatment of patients who are resistant or refractory to existing JAK2 therapies and providing disease modifying effects. Ajax’s lead clinical candidate, AJ1-11095, is the first Type II JAK2 inhibitor to enter the clinic. Type II JAK2 inhibitors have been shown to improve therapeutic efficacy, overcome disease persistence to Type I JAK2 inhibitors, including ruxolitinib, and, most importantly, reduce mutant JAK2 allele burden that drives MPNs. AJ1-11095 is currently in a Phase I study in the US for patients who have been failed by a Type I JAK2 inhibitor.

ajaxtherapeutics.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.